CONFERENCE PROCEEDING
Compliance with smoke-free legislation in six European countries (2016): findings from the ITC 6 European country survey (EUREST-PLUS project)
 
More details
Hide details
1
Catalan Institute of Oncology (ICO)
2
Bellvitge Biomedical Research Institute (IDIBELL)
3
University of Waterloo, Canada
4
Ontario Institute for Cancer Research, Canada
5
University of Crete, Greece
6
European Network for Smoking and Tobacco Prevention (ENSP), Belgium
Publish date: 2018-06-13
 
Tob. Prev. Cessation 2018;4(Supplement):A187
KEYWORDS:
ABSTRACT:
Introduction:
Aim: To describe the prevalence of smoking in workplaces and key hospitalities venues in 6 European countries.

Material and Methods:
We used baseline data (2016) of the International Tobacco Control 6 European (ITC 6E Country Survey) under the EUREST-PLUS Project and part of the larger ITC Project, conducted in national representative samples of 1,000 adult smokers aged 18 and older per country in Germany, Greece, Hungary, Poland, Romania, and Spain. For each venue (workplaces, restaurants, bars/pubs, and discos), participants were asked if: (1) there were people smoking during their last visit and (2) whether they themselves had smoked. We report the weighted prevalence of seeing smoking and smoking in each venue overall and by country.

Results:
Overall, prevalence of smoking as seen by participants was 18.8% in workplaces, with high variability among countries (from 4.7% in Hungary to 40.8% in Greece). Among participants visiting hospitality venues in the last year, 22.7% had seen smoking in restaurants (12.2% had themselves smoked), 33.9% had seen smoking in pubs/bars (20.4% had themselves smoked) and 44.8% had seen smoking in discos (34.8% had themselves smoked).

Conclusions:
Compliance with smoke-free bans in public places is higher in workplaces than in hospitality venues in Europe, with high variability among countries. More extensive awareness campaigns are needed to increase the compliance of smoke-free regulations, especially in leisure facilities.

Funding:
The EUREST-PLUS Study takes place with the financial support of the European Commission, Horizon 2020 HCO-6-2015 program (EUREST-PLUS: 681109; C. Vardavas) and the University of Waterloo (GT. Fong). Additional support was provided to the University of Waterloo by the Canadian Institutes of Health Research (FDN-148477). GT. Fong was supported by a Senior Investigator Grant from the Ontario Institute for Cancer Research.

CORRESPONDING AUTHOR:
Esteve Fernández   
Catalan Institute of Oncology (ICO)
eISSN:2459-3087